Longitudinal study of patients after surgical treatment for cervical lesions: Detection of HPV DNA and prevalence of HPV-specific antibodies

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 25, Issue 8, 2006, Pages 492-500

  Tachezy, R ^a   Mikyskova I ^a   Ludvikova V ^a   Rob, L ^b   Kucera T ^a   Slavik V ^c   Bekova A ^c   Robova H ^b   Pluta, M ^b   Hamsikova E ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Centre of Gynecology Oncology Prevention   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; COLPOSCOPY; CONTROLLED STUDY; DOT HYBRIDIZATION; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SEXUAL BEHAVIOR; SMOKING; SOUTHERN BLOTTING; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS;

EID: 33747356514     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-006-0172-5     Document Type: Article

References (38)

1. Bollen LJ, Tjong-A-Hung SP, van der Velden J, Mol BW, ten Kate FW, ter Schegget J, Bleker OP (1999) Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol Oncol 72:199-201
2. Loizzi P, Carriero C, Di Gesu A, Resta L, Nappi R (1992) Rational use of cryosurgery and cold knife conization for treatment of cervical intraepithelial neoplasia. Eur J Gynaecol Oncol 13:507-513
3. Elfgren K, Bistoletti P, Dillner L, Walboomers JM, Meijer CJ, Dillner J (1996) Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol 174:937-942
4. Kanamori Y, Kigawa J, Minagawa Y, Irie T, Oishi T, Itamochi H, Cheng X, Terakawa N (1998) Residual disease and presence of human papillomavirus after conization. Oncology 55:517-520
5. Chua KL, Hjerpe A (1997) Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol 66:108-113
6. Nagai Y, Maehama T, Asato T, Kanazawa K (2000) Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 79:294-299
7. Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang KG, Huang HJ, Chao A (2001) Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. Am J Obstet Gynecol 184:940-945
8. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, Voorhorst FJ, van Kemenade FJ, Rozendaal L, Meijer CJ (2004) HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 59:543-553
9. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87:1365-1371
10. IARC Working Group (1995) Human papillomaviruses. IARC, Lyon, France
11. Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M, Burk RD, Kurman RJ, Wacholder S, Rush BB, Cadell DM, Lawler P, Tabor D, Schiffman M (1999) Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 91:954-960
12. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19
13. de Roda Husman AM, Walboomers JM, Meijer CJ, Risse EK, Schipper ME, Helmerhorst TM, Bleker OP, Delius H, van den Brule AJ, Snijders PJ (1994) Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. Int J Cancer 56:802-806
14. Ho L, Chan S-Y, Burk RD, Das BC, Fujinaga K, Icenogle JP, Kahn T, Kiviat N, Lancaster W, Mavromara-Nazos P, Labropoulou V, Mitrani-Rosenbaum S, Norrild B, Pillai MR, Stoerker J, Syrjänen K, Syrjänen SM, Tay S-K, Villa LL, Wheeler CM,Williamson A-L, Bernard H-U (1993) The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 67:6413-6423
15. Tornesello ML, Buonaguro FM, Meglio A, Buonaguro L, Beth GE, Giraldo G (1997) Sequence variations and viral genomic state of human papillomavirus type 16 in penile carcinomas from Ugandan patients. J Gen Virol 78:2199-2208
16. Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA (1995) Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol 69:7743-7753
17. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM (1997) Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 71:2463-2472
18. Xi LF, Koutsky LA, Galloway DA, Kuypers J, Hughes JP, Wheeler CM, Holmes KK, Kiviat NB (1997) Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 89:796-802
19. Hildesheim A, Wang SS (2002) Host and viral genetics and risk of cervical cancer: a review. Virus Res 89:229-240
20. Tornesello ML, Duraturo ML, Salatiello I, Buonaguro L, Losito S, Botti G, Stellato G, Greggi S, Piccoli R, Pilotti S, Stefanon B, De PG, Franceschi S, Buonaguro FM (2004) Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol 74:117-126
21. Franco EL, Villa LL, Rahal P, Ruiz A (1994) Molecular variant analysis as an epidemiological tool to study persistence of cervical human papillomavirus infection. J Natl Cancer Inst 86:1558-1559
22. van Belkum A, Juffermans L, Schrauwen L, van Doornum G, Burger M, Quint W (1995) Genotyping human papillomavirus type 16 isolates from persistently infected promiscuous individuals and cervical neoplasia patients. J Clin Microbiol 33:2957-2962
23. Tachezy R, Hamsikova E, Hajek T, Mikyskova I, Smahel M, Van Ranst M, Kanka J, Havrankova A, Rob L, Guttner V, Slavik V, Anton M, Kratochvil B, Kotrsova L, Vonka V (1999) Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol 58:378-386
24. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM (1991) Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265:472-477
25. Xi LF, Demers W, Kiviat NB, Kuypers J, Beckmann AM, Galloway DA (1993) Sequence variation in the noncoding region of human papillomavirus type 16 detected by single-strand conformation polymorphism analysis. J Infect Dis 168:610-617
26. Hamšíková E, Ludvíková V, Šmahel M, Sapp M, Vonka V (1998) Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic. Int J Cancer 77:689-694
27. IARC Working Group (2005) IARC handbooks of cancer prevention: cervix cancer screening. IARC, Lyon, France
28. Chao A, Lin CT, Hsueh S, Chou HH, Chang TC, Chen MY, Lai CH (2004) Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization. Am J Obstet Gynecol 190:1046-1051
29. Houfflin Debarge V, Collinet P, Vinatier D, Ego A, Dewilde A, Boman F, Leroy JL (2003) Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. Gynecol Oncol 90:587-592
30. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ (2001) Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358:1782-1783
31. Hamšíková E, Ludvíková V, Tachezy R, Kovařík J, Břoušková L, Vonka V (2000) Longitudinal follow-up of antibody response to selected antigens of human papillomaviruses and herpes viruses in patients with invasive cervical carcinoma. Int J Cancer 86:351-355
32. Dillner J (1993) Disappearance of antibodies to HPV 16 E7 after treatment for cervical cancer. Lancet 341:1594
33. Fisher SG, Benitez-Bribiesca L, Nindl I, Stockfleth E, Muller M, Wolf H, Perez-Garcia F, Guzman-Gaona J, Gutierrez-Delgado F, Irvin W, Gissmann L (1996) The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer. Gynecol Oncol 61:73-78
34. Baay MFD, Duk JM, Burger MPM, Debruijn HWA, Stolz E, Herbrink P (1999) Humoral immune response against proteins E6 and E7 in cervical carcinoma patients positive for human papilloma virus type 16 during treatment and follow-up. Eur J Clin Microbiol Infect Dis 18:126-132
35. Xi LF, Demers W, Kiviat NB, Kuypers J, Beckmann AM, Galloway DA (1993) Sequence variation in the noncoding region of human papillomavirus type 16 detected by single-strand conformation polymorphism analysis. J Infect Dis 168:610-617
36. Mayrand MH, Coutlee F, Hankins C, Lapointe N, Forest P, de Ladurantaye M, Roger M (2000) Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J Clin Microbiol 38:3388-3393
37. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A (1996) Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 69:364-368
38. Zehbe I, Wilander E, Delius H, Tommasino M (1998) Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 58:829-833